This site is intended for Healthcare professionals only.

Lupin gets market approval of Atovaquone oral suspension By USFDA


Lupin gets market approval of Atovaquone oral suspension By USFDA

Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.

New Delhi: Drug firm Lupin said it has received a approval from the US health regulator to market its Atovaquone oral suspension used for prevention and treatment of a type of pneumonia. The company has received approval to market generic Atovaquone oral suspension USP in the strength of 750 mg/5 mL from the United States Food and Drug Administration (USFDA), Lupin said in a BSE filing.

The product is a generic version of GlaxoSmithKline LLC’s Mepron oral suspension in the same strength, it added.

As per IQVIA MAT June 2018 data, Atovaquone oral suspension, 750 mg/5 mL had annual sales of around USD 117.4 million in the US, Lupin said.

The product is “indicated for the prevention and acute oral treatment of mild-to-moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole,” it added.



Source: PTI
0 comment(s) on Lupin gets market approval of Atovaquone oral suspension By USFDA

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted